PDGFRB and gastrointestinal stromal tumor: In KIT-mutated gastro intestinal stromal tumors (GIST), treatment with imatinib, a selective inhibitor targeting KIT, ABL, and platelet-derived growth factor receptor (PDGFR), results in an overall response rate of approximately 50% in patients with durable responses and a median progression-free survival of 18 months [14].